7 Congenital Heart Disease Associated with Pulmonary
7. CONCLUSIONS
9. van Albada ME, Shoemaker RG, Kemna MS, et al. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J.
2005; 26:487–493.
10. Black SM, Bekker JM, Johengen MJ, et al. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 2000; 47:97–106.
11. Fratz S, Meyrick B, Ovadia B, et al. Chronic endothelin A Receptor blockade in lambs with increased pulmonary blood flow and pressure.
Am J Physiol Lung Cell Mol Physiol 2004; 287:L592–L597.
12. Mata-Greenwood E, Meyrick B, Soifer SJ, Fineman JR, Black SM.
Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol 2003; 285:L222–L231.
13. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM.
Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2003; 285:L209–L221.
14. Cornfield DN, Resnik ER, Herron JM, Reinhartz O, Fineman JR.
Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease. Am J Physiol Lung Cell Mol Physiol 2002;
283:L1210–L1219.
15. Black SM, Sanchez LS, Mata-Greenwood E, et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;
281:L1051–L1057.
16. Van Beneden R, Rondelet B, Kerbaul F, Ray L, Naeje R. Ang-1/BMPR2 signalling and the expression of MCP-1 and ICAM in overcirculation-induced experimental pulmonary hypertension. Eur Respir J 2004;
24:533 S.
17. Rondelet B, Kerbaul F, Motte S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Circulation 2003; 107:1329–1335.
18. Rondelet B, Kerbaul F, Van Beneden R, et al. Signalling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004; 110:2220–2225.
19. Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease.
Circulation 2002; 106:92–99.
20. Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993; 71:
448–450.
21. Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair.
J Thorac Cardiovasc Surg 1995; 110:271–273.
22. Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997; 33:196–200.
23. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004; 24:371–374.
24. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76:1037–1042.
25. Batista RJ, Santos JL, Takeshita N, et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol. 1997 Apr;
68(4):279–280.
26. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996; 112:1600–1607.
27. Schulze-Neick I, Li J, Penny DJ et al. Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery.
J Thorac Cardiovasc Surg 2001; 121:1033–1039.
28. Adatia I, Barrow S, Stratton P, et al. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J 1994; 72:452–456.
29. Schulze-Nieck I, Penny DJ, Rigby ML, et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation 1999; 100:749–755.
30. Hiramatsu T, Imai Y, Takanishsi Y, et al. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann Thorac Surg 1997; 63:648–652.
31. Bradley SM, Simsic JM, Mulvihill DM. Hypoventilation improves oxygenation after bidirectional superior cavopulmonary connection, J Thorac Cardiovasc Surg 2003; 126:1033–1039.
32. Hoskote A, Li J, Hickey C, et al. The effects of carbon dioxide on oxygenation and systemic, cerebral and pulmonary vascular hemody-namics after the bidirectional superior cavopulmonary anastomosis. J Am Coll Cardiol 2004; 44:1501–1509.
33. Guadagni G, Bove EL, Migliavacca F, Dubini G. Effects of pulmonary afterload on the hemodynamics after the hemi-Fontan procedure. Med Eng Phys 2001; 23:293–298.
34. Ikai A, Shirai M, Nishimura K, et al. Hypoxic pulmonary vasoconstriction disappears in a rabbit model of cavopulmonary shunt. J Thorac Cardiovasc Surg 2004; 127:1450–1457.
35. Simsic JM, Bradley SM, Mulvihill DM. Sodium nitroprusside after bidirectional superior cavopulmonary connection: preserved cerebral blood flow velocity and systemic oxygenation. J Thorac Cardiovasc Surg 2003; 126:186–190.
36. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845–1855.
37. Saha A, Balakrishnan K, Jaiswal P, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994; 45:
199–207.
38. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Int Med 1998; 128:745–755.
39. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999; 84:677–681.
40. Sondel PM, Tripp ME, Ganick DJ, Levy JM, Shahidi NT. Phlebotomy with iron therapy to correct the microcytic polycythemia of chronic hypoxia. Pediatrics 1981; 67:667–670.
41. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993; 87:1954–1959.
42. Jones P, Patel A. Eisenmenger’s syndrome and problems with anaesthesia.
Br J Hosp Med 1996; 54(5):214–219.
43. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long-term oxygen treatment at home in children with pulmonary vascular disease.
Br Heart J 1986; 55:385–390.
44. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger Syndrome. Am J Respir Crit Care Med 2001; 164:1682–1687.
45. Gildein HP, Wildberg A, Moellin R. Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome. Z Kardiol (Germany) 1995; 84:55–63.
46. Trulock EP. Lung transplantation for primary pulmonary hypertension.
Clin Chest Med 2001; 22:583–593.
47. Silversides CK, Granton JT, Konen T, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003;
42:1982–1987.
48. Rosove MH, Hocking WG, Harwig SS, Perloff JK. Studies of beta-thromboglobulin, platelet factor 4, fibrinopeptide-A in erythrocytosis due to cyanotic congenital heart disease. Thromb Res 1983; 29:225–235.
49. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circu-lation 1999; 99:1858–1865.
50. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: As case series. Ann Intern Med 1999; 130:740.
51. Ferndandes SM , Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau KK, Landzberg MJ. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003; 91:46–49.
52. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322–329.
53. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intra-venous epoprostenol (prostacyclin) with conventional therapy for primary
pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296–302.
54. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800–804.
55. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hyper-tension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496–502.
56. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896–903.
57. Barst RJ, Langleben D, Frost A, Horn EM, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;
169:441–447.
58. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48–54.